Jeremy King1, Michael Bouvet2, Gagandeep Singh3, John Williams1. 1. Department of Molecular Medicine, Beckman Research Institute at City of Hope, Duarte, California. 2. Department of Surgery, University of California San Diego, San Diego, California. 3. Department of Surgery, City of Hope, Duarte, California.
Abstract
BACKGROUND: Pancreatic cancer is the fourth most deadly cancer in the United States, and is expected to be the second most deadly by 2030. The major difficulty in treating pancreatic cancer is the late onset of symptoms. Generally, patients show metastatic disease by the time of diagnosis, with a survival rate of 5% beyond 5 years. In patients without metastatic disease, surgical resection increases 5 year survival rate to 25%. The remaining 75% succumb to undetected metastases. Clearly, improvements to both detection, surgical intervention, and therapeutic strategies will be needed to improve patient outcome in pancreatic cancer. METHODS: Recent literature has been surveyed and atomic models of new therapeutic approaches were generated. RESULTS AND CONCLUSIONS: Here, we focus on the recent progress employing monoclonal antibodies (mAbs) to target pancreatic cancer associated markers, and more specifically on recent chemical and protein engineering efforts to improve the homogeneity, stability, and administration of mAbs to precisely deliver imaging agents and cytotoxins to sites of disease.
BACKGROUND:Pancreatic cancer is the fourth most deadly cancer in the United States, and is expected to be the second most deadly by 2030. The major difficulty in treating pancreatic cancer is the late onset of symptoms. Generally, patients show metastatic disease by the time of diagnosis, with a survival rate of 5% beyond 5 years. In patients without metastatic disease, surgical resection increases 5 year survival rate to 25%. The remaining 75% succumb to undetected metastases. Clearly, improvements to both detection, surgical intervention, and therapeutic strategies will be needed to improve patient outcome in pancreatic cancer. METHODS: Recent literature has been surveyed and atomic models of new therapeutic approaches were generated. RESULTS AND CONCLUSIONS: Here, we focus on the recent progress employing monoclonal antibodies (mAbs) to target pancreatic cancer associated markers, and more specifically on recent chemical and protein engineering efforts to improve the homogeneity, stability, and administration of mAbs to precisely deliver imaging agents and cytotoxins to sites of disease.
Authors: H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne Journal: Nucleic Acids Res Date: 2000-01-01 Impact factor: 16.971
Authors: F Lhospice; D Brégeon; C Belmant; P Dennler; A Chiotellis; E Fischer; L Gauthier; A Boëdec; H Rispaud; S Savard-Chambard; A Represa; N Schneider; C Paturel; M Sapet; C Delcambre; S Ingoure; N Viaud; C Bonnafous; R Schibli; F Romagné Journal: Mol Pharm Date: 2015-02-09 Impact factor: 4.939
Authors: R Muraro; M Kuroki; D Wunderlich; D J Poole; D Colcher; A Thor; J W Greiner; J F Simpson; A Molinolo; P Noguchi Journal: Cancer Res Date: 1988-08-15 Impact factor: 12.701
Authors: Antoine Maruani; Mark E B Smith; Enrique Miranda; Kerry A Chester; Vijay Chudasama; Stephen Caddick Journal: Nat Commun Date: 2015-03-31 Impact factor: 14.919
Authors: Vanessa Siegmund; Birgit Piater; Bijan Zakeri; Thomas Eichhorn; Frank Fischer; Carl Deutsch; Stefan Becker; Lars Toleikis; Björn Hock; Ulrich A K Betz; Harald Kolmar Journal: Sci Rep Date: 2016-12-16 Impact factor: 4.379
Authors: Elizabeth L Smith; John P Giddens; Anthony T Iavarone; Kamil Godula; Lai-Xi Wang; Carolyn R Bertozzi Journal: Bioconjug Chem Date: 2014-04-07 Impact factor: 4.774
Authors: Thinzar M Lwin; Kentaro Miyake; Takashi Murakami; Jonathan C DeLong; Siamak Amirfakhri; Filemoni Filemoni; Sang Nam Yoon; Paul J Yazaki; John E Shivley; Brian Datnow; Bryan M Clary; Robert M Hoffman; Michael Bouvet Journal: Oncotarget Date: 2018-12-18